Introduction: Agomelatine is a relatively new antidepressant with a mechanism of action that is different from other antidepressants: it is a melatonergic agonist and a 5-HT2C antagonist. It is an effective treatment for depression, with relatively mild side effects. It may be a valuable pharmacological alternative in the clinical approach on depression.
Areas Covered: The literature about agomelatine has been comprehensively reviewed. Agomelatine's efficacy, safety and tolerability are reviewed based on the studies undertaken in patients with major depressive disorder (MDD) and bipolar disorder (BPD).
Expert Opinion: Agomelatine has shown an antidepressant effect in preclinical models, and the results of a large-scale clinical trial program, conducted in MDD, indicate both an antidepressant activity and a favorable tolerability profile. Agomelatine has no discontinuation syndrome, sexual discomfort is rare, and it is generally weigh neutral. The drug appears to be relatively safe in case of overdose. However, some cases of elevated hepatic transaminases are reported during treatment. As agomelatine has a mechanism of action that differs from other agents, it may represent a valuable additional treatment option in those patients who do not respond fully or who do not tolerate the side effects of other antidepressants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14740338.2013.828690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Agomelatine bears promising potential in treating bipolar depression- a systematic review.
Int J Psychiatry Clin Pract
December 2024
Department of Psychiatry, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction: The controversy of antidepressant use in bipolar depression remains controversial. Agomelatine (AGO) is an effective antidepressant in major depressive disorder (MDD), but its application in bipolar depression was little discussed. We aimed to provide a comprehensive systematic review of clinical evidence from studies examining the efficacy and safety of AGO for bipolar depression.
View Article and Find Full Text PDFEfficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis.
Int J Mol Sci
November 2024
Department of Pharmacology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
Major depressive disorder (MDD) and diabetes mellitus (DM) remain among the most prevalent diseases and the most significant challenges faced by medicine in the 21st century. The frequent co-occurrence and bidirectional relationship between the two conditions necessitates the identification of treatment strategies that benefit both. The purpose of this study was to systematically review and meta-analyze data on the efficacy and safety of agomelatine (AGO) in the treatment of patients with depression with comorbid diabetes to explore its potential mechanism of action in both diseases and its impact on diabetic parameters.
View Article and Find Full Text PDFAgomelatine as Antidepressant Treatment in Elderly Patients With Previous Hyponatremia Due To SSRI Use: Case Series.
Hum Psychopharmacol
January 2025
Departamento de Psiquiatría, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Objective: To evaluate agomelatine treatment in elderly patients with major depressive disorder (MDD) who developed hyponatremia while using selective serotonin receptor inhibitors (SSRIs).
Methods: Patients (60 years or older) with hyponatremia after SSRI treatment for MDD were changed to agomelatine 50 mg/day during one month to observe sodium levels during the treatment and change in depressive symptoms. Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale (CGI) of severity were used before and after treatment with agomelatine.
Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: A systematic review and network meta-analysis.
Andrology
September 2024
Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.
Introduction: Antidepressants may lead to a series of sexual adverse effects (SAEs), among which ejaculation dysfunction (EjD) is often overlooked by clinicians. The purpose of the present network meta-analysis was to assist drug adjustment by comparing and ranking the incidence of EjD among various antidepressants.
Methods: Relevant studies were retrieved from PubMed, Embase, Scopus, Web of Science, ClinicalTrials.
[Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression].
Zh Nevrol Psikhiatr Im S S Korsakova
September 2024
Mental Health Research Center, Moscow, Russia.
Article Synopsis
- - The article reviews the effectiveness of agomelatine used alongside antipsychotics for treating post-schizophrenic depression (PSD), based on data from 5 studies involving 137 patients over therapy durations of 28 to 180 days.
- - Results indicated a significant improvement in patient symptoms and remission rates, alongside a good safety and tolerability profile for agomelatine.
- - However, the review highlights methodological limitations, such as small sample sizes and lack of controlled trials, suggesting the need for more rigorous studies to validate these findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!